Quality challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer. Group for Evaluation of Prognostic Factors in Immunohistochemistry in Breast Cancer (GEFPICS)
Penault-Llorca, F.; Jacquemier, J.; Le Doussal, V.; Voigt, J.J.
Annales de Pathologie 19(4): 280-282
1999
ISSN/ISBN: 0242-6498 PMID: 10544761 Document Number: 509162
Document emailed within 1 workday
Related Documents
Zore, Z.; Stanec, M.; Milas, I.; Penavić, I.; Oresić, T.; Roth, A.; Muzina, D. 2012: Epidemiology of invasive breast cancer according to histopathologic and immunohistochemistry prognostic factors Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 66(4): 315-320Balaton, A.L.; Coindre, J.M.; Collin, F.; Ettore, F.; Fiche, M.; Jacquemier, J.; Le Doussal, V.; Mandard, A.M.; Mathieu, M.C.; Migeon, C.; Simony-Lafontaine, J.; Treilleux, I.; Verriele, V.; Vilain, M.O.; Zafrani, B. 1996: Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. Study Group on Hormone Receptors using Immunohistochemistry FNCLCC/AFAQAP. National Federation of Centres to Combat Cancer/French Association for Quality Assurance in Pathology Annales de Pathologie 16(2): 144-148
Kounelis, S.; Kapranos, N.; Malamos, N.; Kouri-Bairaktari, E. 2005: Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry Anticancer Research 25(2a): 939-946
Noel, P.; Chauvin, F.; Michot, J.P.; Catimel, G.; Hesch, M.; Groleas, M. 1991: Prognostic value of lympho node micrometastases detected by immunohistochemistry. Study of 168 cases of breast cancer with a 10-year follow-up Annales de Pathologie 11(5-6): 309-315
Li, H.-H.; Ma, F.; Zeng, X.; Wang, J.-Y.; Yuan, P.; Fan, Y.; Xu, B.-H. 2011: Comparison of fluorescence in situ hybridization and immunohistochemistry assessment for Her-2 status in breast cancer and its relationship to clinicopathological characteristics Zhonghua Yi Xue Za Zhi 91(2): 76-80
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176
Bouchalová, K.; Trojanec, R.; Kolár, Z.; Cwiertka, K.; Cernáková, I.; Mihál, V.; Hajdúch, M. 2006: Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer Neoplasma 53(5): 393-401
Larsimont, D.; Di Leo, A.; Rouas, G.; Paesmans, M.; Ferreira-Filho, F.; Bernard, C.; Cardoso, F.; Verhest, A.; Piccart, M.J.; Gancberg, D. 2002: HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice Anticancer Research 22(4): 2485-2490
Váian, P.; Velecký, J.; Gatek, J. 2007: Assessment of sentinel nodes in breast cancer by rapid peroperative biopsy and immunohistochemistry in serial sectioning Ceskoslovenska Patologie 43(1): 13-17
Rudan, I.; Skorić, T.; Rudan, N. 1994: Breast cancer prognosis. II. Prognostic factors in patients with node-positive (N1-3) breast cancer Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 48(4-5): 165-170
Rudan, I.; Skorić, T.; Rudan, N. 1994: Breast cancer prognosis. I. Prognostic factors in patients with node-negative (N0) breast cancer Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 48(4-5): 159-163
Dueñas González, A.; Cruz Hernández, J.J.; Abad Hernández, M.M.; Ramos, M.; González Sarmiento, R. 1996: Greater sensitivity of the PCR-SSCP technique compared with immunohistochemistry for the detection of exon 5 and 6 mutations of gene 53 in breast cancer Medicina Clinica 106(19): 721-724
Nádasdy, T.; Gyöngyösy, M.; Krenács, T. 1988: Simultaneous occurrence of breast cancer, causing disseminated metastases after 32 years verified by immunohistochemistry, and cured malignant melanoma Orvosi Hetilap 129(51): 2743-2746
Chariyalertsak, S.; Chariyalertsak, S.; Cheirsilpa, A.; Chindavijak, K. 1998: Prognostic importance of p53 and c-erbB-2 oncoproteins overexpression in patients with breast cancer Journal of the Medical Association of Thailand 81(9): 698-704
Wright, C.; Angus, B.; Nicholson, S.; Sainsbury, J.R.; Cairns, J.; Gullick, W.J.; Kelly, P.; Harris, A.L.; Horne, C.H. 1989: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer Cancer Research 49(8): 2087-2090
1990: Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group Lancet 335(8705): 1565-1568
Axelsson, C.K.; Andersen, J.A.; Andersen, K.W.; Blichert-Toft, M.; Dombernowsky, P.; Hansen, M.; Krag, C.; Mouridsen, H.T.; Overgaard, M.; Rasmussen, B.B. 1991: Prognosis after surgical treatment of breast cancer. 3. The low-risk group of the DBCG (Danish Breast Cancer Cooperative Group) Ugeskrift for Laeger 153(33): 2276-2279
Aryandono, T.; Harijadi; Ghozali, A. 2000: Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 600-606
Tokunaga, Y.; Nakagami, M.; Tokuka, A.; Ohsumi, K. 2003: Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: immunohistochemistry using a new monoclonal antibody Anticancer Research 23(2C): 1763-1768
Crivellari, D. 2002: Results of adjuvant treatments in breast cancer patients over 70 years old: the IBCSG experience. International Breast Cancer Study Group Tumori 88(1 Suppl. 1): S81-S82